We stand for developing affordable and innovative pharmaceuticals by investing in the latest science and technology, developing great scientists and creating an environment that nurtures innovation in all aspects of product development. In this episode of #ScientistInSpotlight, we hear from Dr. Akhil Kumar, Chief Medical Officer of Aurigene Oncology Limited.

Aurigene Oncology Limited recently announced promising Phase 1 results of Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. In this video, Akhil traces the evolution of the various treatment options in oncology over the last three decades - Chemotherapy, Antibody, Small Molecule, Gene Therapy, Bi-Specific Antibody, Anti-Drug Conjugates and Chimeric Antigen Receptor T-cell (or CAR-T Cell Therapy). And explains the exciting research underway today using oncolytic viruses, mRNA vaccines, and others. A very accessible and informative lesson indeed!

Our #ScientistInSpotlight series is an attempt to capture the pioneering bold vision and pursuit of excellence in deep science on which our company was founded, and which finds expression through our scientists. In turn, our scientists share their journey, learnings and the scientific challenges that keep them going.

#ScientistInSpotlight #OncologyResearch #GoodHealthCantWait #WeAreDrReddys #Innovation #Oncology

свернуть